Spruce biosciences announces topline results from cahmelia-203 in adult classic cah and cahptain-205 in pediatric classic cah

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced topline results from its cahmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (cah) and its cahptain-205 study of tildacerfont in pediatric classic cah. spruce is investigating tildacerfont, a second gen.
SPRB Ratings Summary
SPRB Quant Ranking